Safety & efficacy of obe-cel in R/R ALL: updated findings from the FELIX trial
In this video, Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, shares updated results from the FELIX trial (NCT04404660), which is evaluating the CAR T-cell product obecabtagene autoleucel (obe-cel) in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Dr Barba notes the high efficacy of the treatment, with complete remission rates of over 75% and a good safety profile, including low incidence of cytokine release syndrome (CRS) and infections. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting in Strasbourg, France. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
